

## **PAG-led Sekhmet Pharmaventures ropes in Anil Khubchandani as MD and CEO**

02 June 2023 | News

### **Accomplished industry executive to lead platform on next stage of growth**

A private equity consortium led by PAG, a leading Asia-based investment firm, has hired Anil Khubchandani as Managing Director (MD) and Chief Executive Officer (CEO) of Sekhmet Pharmaventures, an investment platform established to nurture and grow India's next generation of active pharmaceutical ingredient (API) companies.

Anil Khubchandani is an accomplished leader with over 30 years of experience in strategic partnerships, global sales & marketing, operations management, and research & development. In his most recent role, he served as Co-CEO and Whole-time Director of Jubilant Ingrevia, a globally integrated provider of life science ingredients and specialty chemicals, where he focused on business transformation and growth strategy implementation.

Over his 20-year career at Jubilant Ingrevia, Khubchandani also served as a strategic business leader, developed high-performing teams, and oversaw solutions and offerings for pharmaceutical, agrochemical, and other industrial clients. He has spearheaded several global CDMO assignments and new business initiatives for pharmaceutical innovator companies.

Sekhmet Pharmaventures is the India arm of Gamot API, a Singapore-based platform launched by PAG along with Indian private equity firms CX Partners and Samara Capital to buy stakes in fast-growing pharma companies. The platform acquired control of Chennai-based Anjan Drug in October 2020 and the Hyderabad-based Optimus Drugs group of companies in September 2022. Gamot API is majority owned by PAG, which has invested over \$1.5 billion in India across its private equity and private debt businesses.